Date: Feb 19, 2015 Author: Brian Feldt Source: bizjournals (
click here to go to the source)
Vasculox, a St. Louis-based pharmaceutical discovery startup, has raised $1.27 million from a group of investors, according to a filing with the U.S. Securites and Exchange Commission.
Those investors include RiverVest Venture Partners, which invested $500,000 in the deal, the BioGenerator ($250,000) and the Missouri Technology Corporation (MTC).
Vasculox is focused on developing drugs for disorders including leukemia, lymphoma and solid tumors. The company will use the money to continue development of its drugs, said CEO Bob Karr.
Karr said he doesn't expect to bring the drug to market for several years.
Vasculox was already a portfolio company of the MTC and BioGenerator, which has invested about $525,000 into the company to date. The St. Louis Arch Angels have also previously invested in the startup.
The company, which is pre-revenue and has six employees at the BioGenerator Labs at 4320 Forest Park Ave., is led by Karr and CFO Kathleen Beckmann, and was founded by William Frazier, a professor at Washington University.
The company has also received more than $1.7 million since 2009 from the National Heart, Lung and Blood Institute.
